Seven universities and five industrial partners from five European countries to cooperate in the project. The European Commission has awarded €2.7 million to the H2020 project «BIOCASCADES - Sustainable and Scalable Biocatalytic Cascade Reactions Training Network». The project is under the Marie Skłodowska- Curie Innovative Training Networks, specifically in the... read more →
Mar
01
Sep
26
Colorectal cancer (CRC) shows alterations on the activation status of receptor tyrosine kinases (RTKs) and intracellular cytoplasmic kinases, some of which correlate between primary tumors and liver metastases. EC-70124, a kinase inhibitor being developed at EntreChem SL, shows strong antiproliferative effect on CRC by acting on relevant activated targets observed... read more →
Jun
02
Triple Negative Breast Cancer (TNBC) at the molecular level shows alterations on receptor tyrosine kinases (RTKs), downstream signaling pathways involved in the regulation of proliferation and survival, and DNA repair machinery. EC-70124, a kinase inhibitor being developed at EntreChem SL, shows a multi-mode of action on TNBC by inhibiting several... read more →
Jan
08
EntreChem participates in the FP7 European Collaborative Project STREPSYNTH, whose goal is rewiring Streptomyces bacteria as a cell factory for the cost-effective production of biomolecules. The project has been awarded in the last KBBE-FP7 call that focused on synthetic biology, a topic of current high interest both in industry and... read more →
Apr
15
ESE1/ELF3 and NF-kB are co-activated in selected prostate tumors and associated with adverse prognosis in prostate tumors, according to researchers at the IOR (Switzerland). EC-70124, a kinase inhibitor being developed at EntreChem SL, has shown efficacy when administered orally in a murine model of prostate cancer whose malignant phenotype depends... read more →
Jun
22
EntreChem closed a financing round totaling 1 million EUR ($1.25M) with existing shareholders of the company. This all-private funding significantly strengthens the capacities of research and development of the biotech company. These capital contributions help keep 100% ownership under local control, with Francisco Moris confirmed as Managing Director of the... read more →
Apr
16
The fusion protein EWS-FLI1 ins a constitutively activated transcription factor responsible for the oncogenic phenotype of Ewing sarcoma. Mithramycin was identified last year out of 50.000 compounds as a potent inhibitor of EWS-FLI1, according to researchers at the National Cancer Institute and Vanderbilt University (USA). EC-8042, a mithramycin analog (mithralog)... read more →
Mar
26
The PI3K/Akt/PTEN molecular pathway is frequently mutated in this type of tumor, where activation of the Akt kinase is a poor prognosis factor, according to researchers at CIEMAT. EC-70124, a kinase inhibitor under development at EntreChem SL, has shown efficacy in a murine model of Head & Neck cancer that... read more →
May
09
Glioblastoma initiating cells activate NFkB cell signaling pahtway to avoid terminal differentiation, according to researchers in Hospital Valdecilla. EC-70124, an inhibitor of NfkB pathway under development at EntreChem SL, has shown efficacy in murine models of glioblastoma. A multidisciplinar research team from EntreChem SL (Oviedo), Valdecilla Hospital (Santander), University of... read more →
Dec
30
EntreChem announces that Dr Jesús Cortés has joined the company as Director of Molecular Biology. A native of Mexico, Dr Cortés holds a PhD in Microbiology by the University of León, Spain, and has been working in the UK for the last 23 years. During his stay in Cambridge University... read more →
